Barclays
IRD

Barclays’s Opus Genetics IRD Stock Holding History

Barclays’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.9K Buy
13,357
+11,457
+603% +$53.4K ﹤0.01% 4293
2026
Q1 		$8.64K Hold
1,900
– – ﹤0.01% 4718
2025
Q4 		$3.82K Hold
1,900
– – ﹤0.01% 5006
2025
Q3 		$3.13K Hold
1,900
– – ﹤0.01% 5123
2025
Q2 		$1.79K Hold
1,900
– – ﹤0.01% 5043
2025
Q1 		$1.86K Buy
+1,900
New +$2.12K ﹤0.01% 4999
2024
Q4 		– Sell
-1,900
Closed -$2.49K – 5535
2024
Q3 		$2.49K Buy
+1,900
New +$2.92K ﹤0.01% 5069

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's IRD Position: Q2 2026 in Review

Barclays increased its Opus Genetics (IRD) stake by 603% in Q2 2026, buying an estimated $53.4K and bringing the position to 13,357 shares worth $54.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4293.

Barclays first reported a position in IRD in Q3 2024 and has held it in 7 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Barclays held 13,357 shares of Opus Genetics worth $54.9K as of Q2 2026.
  • Barclays bought 11,457 Opus Genetics shares in Q2 2026, an estimated $53.4K.
  • Opus Genetics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4293 holding.
  • Barclays first reported a position in Opus Genetics in Q3 2024 and has held it in 7 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.